Guardian Pharmacy Services (NYSE:GRDN) Given New $43.00 Price Target at Truist Financial

Guardian Pharmacy Services (NYSE:GRDN) had its target price upped by Truist Financial from $38.00 to $43.00 in a research note released on Monday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on GRDN. Raymond James Financial reissued an “outperform” rating and issued a $40.00 price target on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. Jefferies Financial Group began coverage on shares of Guardian Pharmacy Services in a research note on Monday, March 30th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Stephens raised their price objective on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $40.20.

Guardian Pharmacy Services Trading Up 0.6%

NYSE:GRDN opened at $39.40 on Monday. The company’s 50-day moving average price is $34.79 and its 200-day moving average price is $30.86. The company has a market cap of $2.49 billion, a P/E ratio of 51.17 and a beta of 0.47. Guardian Pharmacy Services has a twelve month low of $19.17 and a twelve month high of $41.36.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.10. The firm had revenue of $397.62 million for the quarter, compared to the consensus estimate of $390.04 million. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. Guardian Pharmacy Services’s quarterly revenue was up 17.4% on a year-over-year basis. On average, analysts expect that Guardian Pharmacy Services will post 0.87 earnings per share for the current year.

Insider Buying and Selling at Guardian Pharmacy Services

In other Guardian Pharmacy Services news, Director John Ackerman sold 1,103,364 shares of Guardian Pharmacy Services stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $32,747,843.52. Following the completion of the sale, the director directly owned 345,123 shares in the company, valued at $10,243,250.64. This trade represents a 76.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David K. Morris sold 187,855 shares of Guardian Pharmacy Services stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $5,575,536.40. Following the sale, the insider owned 254,472 shares of the company’s stock, valued at approximately $7,552,728.96. This represents a 42.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 9,726,405 shares of company stock valued at $288,679,700. 32.96% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of institutional investors have recently made changes to their positions in GRDN. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Guardian Pharmacy Services during the first quarter valued at about $233,000. JPMorgan Chase & Co. increased its position in shares of Guardian Pharmacy Services by 48.0% during the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after acquiring an additional 1,956 shares during the last quarter. Legal & General Group Plc increased its position in shares of Guardian Pharmacy Services by 1,783.1% during the second quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock valued at $317,000 after acquiring an additional 14,104 shares during the last quarter. Rhumbline Advisers increased its position in shares of Guardian Pharmacy Services by 121.1% during the second quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock valued at $345,000 after acquiring an additional 8,860 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Guardian Pharmacy Services in the second quarter valued at approximately $214,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.